Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia.

Literature DB >> 15949668

A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia.

S H Fatemi, J M Stary, D K Hatsukami, S E Murphy.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2005 PMID： 15949668 DOI： 10.1016/j.schres.2005.02.021

Source DB: PubMed Journal: Schizophr Res ISSN： 0920-9964 Impact factor: 4.939

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Interventions for the metabolic syndrome in schizophrenia: a review.

Authors: Evangelos Papanastasiou
Journal: Ther Adv Endocrinol Metab Date: 2012-10 Impact factor: 3.565

2. A smoking ban in psychiatric units: threat or opportunity?

Authors: Lindsay Banham; Simon Gilbody; Helen Lester
Journal: Ment Health Fam Med Date: 2008-09

3. Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

Authors: Karolina Kozak; Tony P George
Journal: Expert Opin Pharmacother Date: 2020-02-03 Impact factor: 3.889

4. A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.

Authors: Mahtab Karkhane Yousefi; Timothy D Folsom; S Hossein Fatemi
Journal: J Addict Res Ther Date: 2011-12-20

Review 5. Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors: Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal: Cochrane Database Syst Rev Date: 2013-02-28

Review 6. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306

A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia.

1. Interventions for the metabolic syndrome in schizophrenia: a review.

2. A smoking ban in psychiatric units: threat or opportunity?

3. Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

4. A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.

Review 5. Interventions for smoking cessation and reduction in individuals with schizophrenia.

Review 6. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

7. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.

Review 8. Interventions to reduce harm from continued tobacco use.

9. Smoking reduction interventions for smoking cessation.

Review 10. Antidepressants for smoking cessation.